secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001437749-24-030661
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics appoints Graff President, Iglesias CMO, Høiland Advisor to advance stenoparib
--------------------------------------------------------------------------------

- Jeremy Graff, Ph.D., named President & CDO; base salary $475K, RSUs $250K, signing bonus $75K.
- Jose Iglesias, M.D., appointed Consultant CMO; led Phase III Abraxane development at Celgene.
- Jesper Høiland, former President of Novo Nordisk U.S., joins as Strategic Advisor for commercial strategy.
- Appointments target accelerating stenoparib, a dual PARP/Tankyrase inhibitor, for advanced ovarian cancer.
- Graff previously consulted for Allarity since Dec 2023; brings 25+ years pharma experience including 17 at Eli Lilly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/0001437749-24-030661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/allr20241002_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer